IT’S NOT ALL about shedding pounds and curbing hunger. GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user.

Medicare won't seek to negotiate lower prices for Eli Lilly's popular diabetes drug Mounjaro and weight loss drug Zepbound because they haven't been on the market long enough to be eligible.

LLY Appears to Fall in Sympathy LLY, which sells its own weight loss drug, Zepbound, seems to be falling in sympathy with NVO today. Investors may believe that Zepbound’s prices will also have ...

A new generation of obesity drugs like Novo Nordisk A/S’s Wegovy and Eli Lilly & Co.’s Zepbound is changing the conversation around obesity, its causes and how to cure it. To get better ...

Mounjaro and Zepbound, the competitor diabetes and obesity products made by American pharmaceutical company Eli Lilly, were not selected for this round of drug price negotiations. Lilly’s drug ...

Meanwhile, Leerink Partners analysts doubled down on their confidence in Zepbound's long-term market share. Novo is already licking its wounds from another setbackits experimental two-drug combo ...

Results from a separate trial that were released in 2022 showed patients taking a high dose of Lilly's (LLY.N), opens new tab Zepbound saw more than 20% weight loss. "The results give us greater ...

Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse ...

Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro added $3.5 billion, while obesity drug Zepbound ...